Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Breast Cancer Research

Table 2 Multivariable hazard ratios for risk of disease recurrence by prognostic factors in centrally confirmed HER2+ placebo patients in TEACH

Prognostic factor	Hazard ratio (95% CI)	P value
Hormone receptor (HR²) status	0.59 (0.42, 0.81)	0.002
HR+ vs. HR-, 1–5 yrs after diagnosis
HR+ vs. HR-, 6–10 yrs after diagnosis	0.97 (0.59, 1.62)	0.92
Age at diagnosis (years)
≥40 vs. <40	0.69 (0.49, 0.96)	0.03
Nodal status
Negative vs. positive	0.62 (0.45, 0.87)	0.006
Stage
T1 N0 vs. other	0.58 (0.33, 1.0)	0.05
Prior chemotherapy¹
Anthracycline versus no anthracycline	0.78 (0.38, 1.61)	0.51
Anthracycline + taxane versus anthracycline alone	0.85 (0.64, 1.14)	0.27

¹Separate models, each including all other prognostic factors, were used to estimate the hazard ratio for anthracycline versus no anthracycline and anthracycline with taxane versus anthracycline alone; ²HR+ = ER+ or PR+; HR- = ER- and PR-. The hazard ratio estimate for each prognostic factor is adjusted for all other factors listed in the table. HER2+, human epidermal growth factor receptor 2 positive; TEACH, Tykerb evaluation after chemotherapy; CI, confidence interval.

ISSN: 1465-542X